Javed Butler, MD, MPH, MBA (Activity Chair)
President, Baylor Scott and White Research Institute
Patrick H Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
University of Mississippi Medical Center
Jackson, MS

   Stefan D. Anker, MD, PhD
Professor of Cardiology and Cachexia Research
Department of Cardiology
Charite University
Berlin, Germany

    Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
                                          Medicine Chief, DeBakey VA Medical Center
                                          Houston, TX

   Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Harvard Medical School
Brigham and Women’s Hospital
Cardiovascular Medicine
Boston, MA

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners:
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Muthiah Vaduganathan, MD, MPH—has disclosed that he receives research support from AstraZeneca, Bayer AG, Boeringer Ingelheim, Galmed, Impulse Dynamics, Novartis, Occlutech, and Roche Diagnostics; is on the advisory panel for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; and is on the speaker’s bureau for Novartis and Roche Diagnostics.

Authors/Faculty:
Stefan D. Anker, MD, PhD—has disclosed that he is a consultant for AstraZeneca, Bayer AG, Boehringer Ingelheim, and Novartis; and receives grant/research support from Abbott Laboratories and Vifor.

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP—has disclosed that she is on the advisory panel of Amgen, AstraZeneca, and Boehringer Ingelheim; was on the advisory panel of Baxter, Sanofi-Aventis, and scPharmaceuticals; and receives other financial or material support from Abbott Laboratories, Cardurion Pharmaceuticals, LivaNova, Renovacor, Respicardia, and Vifor Pharma.

Javed Butler, MD, MPH, MBA—has disclosed that he is a consultant for Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmacueticals, Impulse Dynamics, Innolife, Janssen, Luitpold Pharmacueticals, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, and Vifor Pharma; and is on the speaker’s bureau for AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis.

Muthiah Vaduganathan, MD, MPH—has disclosed that he receives research support from AstraZeneca, Bayer AG, Boeringer Ingelheim, Galmed, Impulse Dynamics, Novartis, Occlutech, and Roche Diagnostics; is on the advisory panel for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; and is on the speaker’s bureau for Novartis and Roche Diagnostics.

Peer Reviewers:

Jennifer Cook–has disclosed that she is an employee of Itmar Medical.

Robert Didomenico–has disclosed that he is on the advisory panel for ABIOMED and PhaseBio and he receives grant/research support from CSL Behring.

Daniel Garry–has disclosed that he is a board member for NorthStar Genomics.

David Lanfear–has disclosed that he is a consultant for Abbott Laboratories, Amgen, AstraZeneca, Janssen, Martin Pharmaceuticals. Receives grant/research support from Lilly and SomaLogic and is on the advisory panetl for Cytokinetics and Illumina.  

Cheryl Westlake–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.